Heron Therapeutics Inc. (HRTX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Heron Therapeutics Inc. (HRTX:NASDAQ), powered by AI.

Current Price
$0.45
P/E Ratio
-3.7
Market Cap
76M
Sector
Healthcare
What is the Heron Therapeutics Inc. stock price forecast?

Heron Therapeutics Inc. is currently trading at $0.45. View real-time AI analysis on Alpha Lenz.

What is Heron Therapeutics Inc. insider trading activity?

View the latest insider trading data for Heron Therapeutics Inc. on Alpha Lenz.

What is Heron Therapeutics Inc.'s P/E ratio?

Heron Therapeutics Inc.'s P/E ratio is -3.7.

Heron Therapeutics Inc.

NASDAQ · HRTX
$0.45-0.01(-3.02%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Heron Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Heron Therapeutics Inc. trades at a P/E of -3.7 (undervalued) with strong ROE of 209.1%. 3Y revenue CAGR of 12.9% highlights clear growth momentum.

Ask for details

Company Overview

Heron Therapeutics Inc. is a biotechnology company dedicated to the development and commercialization of therapeutic treatments to address unmet medical needs. The company's primary focus is on improving the lives of patients suffering from cancer and pain, aiming to enhance the efficacy and safety of treatments in these areas. Heron Therapeutics is notable for its work on innovative drug delivery methods, such as extended-release formulations that aim to optimize the therapeutic effects of medications while minimizing side effects. With a strong emphasis on clinical development, Heron operates at the intersection of pharmacology and patient care, pushing advancements particularly within oncology and postoperative pain management fields. The company’s contributions are significant within the healthcare sector, as they provide potential breakthroughs in the treatment paradigms of serious and prevalent conditions. Furthermore, Heron Therapeutics' innovations can influence both clinical practices and healthcare expenditures by potentially offering alternatives that improve patient outcomes and reduce the need for ongoing intervention.

CEOMr. Craig Alexander Collard
SectorHealthcare
IndustryBiotechnology
Employees122

Company Statistics

FY 2025

Profile

$75.60MMarket Cap
$154.90MRevenue
0.00Shares Out
122Employees

Margins

73.31%Gross
1.98%EBITDA
-1.64%Operating
-13.04%Pre-Tax
-13.04%Net

Valuation

-3.74P/E
5.27P/B
0.49EV/Sales
61.24EV/EBITDA
-2.71P/FCF

Growth (CAGR)

12.89%Rev 3Yr
11.81%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-8.26%ROA
209.08%ROE
-4.33%ROIC

Financial Health

$28.65MCash & Cash Equivalents
$212.90MNet Debt
1685.23%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Heron Therapeutics Inc. (ticker: HRTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 122 employees. Market cap is $76M.

The current price is $0.454 with a P/E ratio of -3.74x and P/B of 5.27x.

ROE is 209.08% and operating margin is -1.64%. Annual revenue is $155M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Heron Therapeutics Inc. (HRTX) Stock Forecast 2026 $0.45 — Price, Financials & Analyst Targets | Alpha Lenz